KBP-7018
KBP-7018 is an orally active, tyrosine kinase-selective multi-kinase inhibitor with an IC50 value of 10 nM against c-KIT, 7.6 nM against RET, and 25 nM against human PDGFR. KBP-7018 improves survival rates in a mouse model of pulmonary fibrosis. KBP-7018 can be used in research related to idiopathic pulmonary fibrosis.
For research use only. We do not sell to patients.
- CAS No.: 1613437-66-3
- Formula: C31H30N4O5
- Molecular Weight:538.59
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[2]|
PDGFRβ 34 nM (IC50) |
PDGFRα 26 nM (IC50) |
CYP3A4 0.087 μM (IC50) |
In Vitro
KBP-7018 potently and selectively inhibits c-KIT (IC50 = 10 nM), RET (IC50 = 7.6 nM) and PDGFR (IC50 = 25 nM) in cell-free kinase assays. Meanwhile, it shows extremely weak inhibitory activity against hERG K+ and exhibits high kinome selectivity[1].
KBP-7018 inhibits h-PDGF-bb-stimulated proliferation of 3T3 fibroblasts in cell-based assays, with an IC50 of 100 nM[1].
KBP-7018 potently inhibits purified PDGFRα (IC50 = 26 nM) and PDGFRβ (IC50 = 34 nM)[2].
KBP-7018 (0.05-80 μM; 10 min) potently inhibits human CYP3A4 (testosterone probe, IC50 = 0.087 μM), weakly inhibits human CYP2C9 (IC50 = 35.2 μM), and shows no inhibitory effect on human CYP1A2, CYP2C19 or CYP2D6 at concentrations up to 80 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
| Species | Dose | Route | AUC0-t | CLplasma | T1/2 | Tmax | AUC | F | Bioavailability | Cmax |
|---|---|---|---|---|---|---|---|---|---|---|
| Mice[1] | 50 mg/kg | p.o. | / | / | 4.3 h | / | 17004 ng·h/mL | 51 % | / | / |
| Rat[1] | 10 mg/kg | p.o. | / | / | 4.8 h | / | 6406 ng·h/mL | 68 % | / | / |
| Dog[1] | 20 mg/kg | p.o. | / | / | 3.3 h | / | 2964 ng·h/mL | 29 % | / | / |
| Mice[2] | 10 mg/kg | i.v. | 6636 ng·h/mL | 1.50 L/h/kg | 0.80 h | 0.25 h | / | / | / | / |
| Mice[2] | 50 mg/kg | p.o. | 17004 ng·h/mL | / | 4.29 h | / | / | / | 51 % | / |
| Rat[2] | 2 mg/kg | i.v. | 1877 ng·h/mL | 1.06 L/h/kg | 1.30 h | 1.00 h | / | / | / | / |
| Rat[2] | 10 mg/kg | p.o. | 6406 ng·h/mL | / | 4.81 h | / | / | / | 68 % | / |
| Dog[2] | 2 mg/kg | i.v. | 1007 ng·h/mL | 1.87 L/h/kg | 2.33 h | 2.00 h | / | / | / | / |
| Dog[2] | 50 mg/kg | p.o. | 5178 ng·h/mL | / | 6.71 h | / | / | / | 21 % | / |
| Monkey[2] | 2 mg/kg | i.v. | 2031 ng·h/mL | 0.49 L/h/kg | 6.82 h | 6 h | / | / | / | / |
| Monkey[2] | 5 mg/kg | p.o. | 2578 ng·h/mL | / | 4.56 h | 6.0 h | / | / | 25 % | 73 ng/mL |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57 mice[1]
-
Dosage:10 mg/kg; 30 mg/kg; 100 mg/kg
-
Administration:p.o.; daily; 28 days
-
Result:Significantly improved the 28-day survival rate in a dose-dependent manner.
Demonstrated sufficient tolerance at all tested doses (10 to 100 mg/kg).
Chemical Information
-
CAS No. 1613437-66-3
-
Molecular Weight 538.59
-
Formula C31H30N4O5
-
SMILES
O=C(C1=CC(NC/2=O)=C(C=C1)C2=C(NC3=CC4=C(N(C(CN5CCOCC5)=O)CC4)C=C3)/C6=CC=CC=C6)OC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Fibrosis/Collagen Morphometry
Fibrosis and collagen morphometry is based on the quantitative visualization of fibrillar collagen deposition in tissue sections using histochemical stains such as Sirius Red (Picrosirius Red) or Masson's trichrome, followed by image-based or polarization-enhanced analysis to estimate collagen proportional area as a surrogate of extracellular matrix accumulation during fibrotic remodeling. Sirius Red combined with polarized light microscopy enhances detection of collagen fibers due to birefringence properties, enabling more specific visualization of collagen type I and III fibrils compared to conventional bright-field histology, while whole-section or region-restricted digital morphometry reduces field-selection bias in fibrosis assessment. Alternative quantitative approaches include second harmonic generation (SHG) and two-photon excited fluorescence microscopy, which enable label-free detection of fibrillar collagen and have been validated against histological staining and biochemica
-
Collagen: Sirius Red Staining
Sirius Red or picrosirius red staining is a histochemical method for visualizing collagen-rich extracellular matrix in tissue sections, and collagen fibers are detected as red-stained structures under bright-field microscopy with enhanced birefringence under polarized light. Picrosirius red is useful for assessing total collagen organization, distribution, and fibrosis burden, but polarized color should not be interpreted as a definitive collagen type I versus type III readout because color is affected by fiber orientation, thickness, and packing.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
Masson’s Trichrome (collagen/trichrome staining) is a histological technique that differentially stains tissue compartments using sequential acidic dyes to distinguish collagen from muscle and cytoplasmic components based on dye affinity and tissue permeability differences, enabling visualization of fibrosis and connective tissue architecture in histological sections. The classical formulation typically uses Weigert's iron hematoxylin for nuclear staining, Biebrich scarlet-acid fuchsin for cytoplasm and muscle, and aniline blue (or light green variants) for collagen, producing a characteristic blue/green collagen signal contrasted against red cytoplasm and dark nuclei. The staining principle relies on selective displacement of smaller dye molecules by larger anionic dyes in collagen-rich regions under controlled acidified conditions, which enhances collagen-specific dye retention. This property makes the method widely used for fibrosis assessment in organs such as heart, liver, lung, a
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
References
[1]. Huang Z, et al. Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis. ACS medicinal chemistry letters. 2017 Nov 09;8(11):1142-1147. [Content Brief]
[2]. Huang Z, et al. Characterization of preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018, a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fibrosis. Drug design, development and therapy. 2015;9:4319-28. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)